Arcus Biosciences (NYSE:RCUS) and Cyclerion Therapeutics (NASDAQ:CYCN) are both small-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their profitability, earnings, dividends, analyst recommendations, risk, valuation and institutional ownership.
Insider and Institutional Ownership
46.7% of Arcus Biosciences shares are owned by institutional investors. Comparatively, 70.7% of Cyclerion Therapeutics shares are owned by institutional investors. 19.2% of Arcus Biosciences shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.
This table compares Arcus Biosciences and Cyclerion Therapeutics’ revenue, earnings per share and valuation.
|Gross Revenue||Price/Sales Ratio||Net Income||Earnings Per Share||Price/Earnings Ratio|
|Arcus Biosciences||$8.35 million||51.72||-$49.59 million||($1.43)||-6.59|
|Cyclerion Therapeutics||N/A||N/A||-$115.25 million||N/A||N/A|
Arcus Biosciences has higher revenue and earnings than Cyclerion Therapeutics.
This is a breakdown of current ratings for Arcus Biosciences and Cyclerion Therapeutics, as reported by MarketBeat.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
Arcus Biosciences currently has a consensus target price of $19.00, indicating a potential upside of 101.70%. Given Arcus Biosciences’ stronger consensus rating and higher probable upside, equities research analysts clearly believe Arcus Biosciences is more favorable than Cyclerion Therapeutics.
This table compares Arcus Biosciences and Cyclerion Therapeutics’ net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
Arcus Biosciences beats Cyclerion Therapeutics on 6 of the 10 factors compared between the two stocks.
About Arcus Biosciences
Arcus Biosciences, Inc., a clinical-stage biopharmaceutical company, engages in developing and commercializing cancer immunotherapies in the United States. The company develops various programs targeting immuno-oncology pathways, including AB928, a dual adenosine receptor antagonist, which is in a Phase I/Ib clinical trial; and AB122, an anti-PD-1 antibody that is in Phase I clinical trial. It is also developing AB154, an anti-T-cell immunoreceptor with Ig and ITIM domains antibody, which is in Phase I trial as monotherapy; and AB680, a small-molecule inhibitor of CD73 that is in Phase I healthy volunteer study. The company has a clinical development collaboration agreement with Strata Oncology, Inc. to evaluate AB122, an anti-PD-1 antibody. Arcus Biosciences, Inc. was founded in 2015 and is headquartered in Hayward, California.
About Cyclerion Therapeutics
There is no company description available for Cyclerion Therapeutics Inc.
Receive News & Ratings for Arcus Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Arcus Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.